@Oldpa1 agree Op....once the market becomes fully aware about IHL 675A ( as a focus for the moment ) and the health benefits of the increased bioavailability and what that means in relation to inflammation related conditions.... all of them imo as we have said...there is no limit on what is possible, both for the health outcomes it will potentially deliver and for the prospects of Incannex as a pharma company...astounding when you think about it....
Slowly as the sector wakes up to the potential of just exactly what cbd is potentially capable of once that increased bioavailablility / cell absorption is understood, then i think the dollars will really pour into the sector and the barriers will really fall away (as they are starting to now)....and Incannex are at the forefront of this process. ( Cardiol is onto it as are a few others ...as we know)
Incannex is among a small number who understood from the outset its about upstream validated product that demonstrates efficacy and safety profile through clinical trial - as recognised / evidenced by the wonderful results achieved so far.....some talked the talk and have fallen away - others stuck to the science and great progress is being made
let the SP play action roll on- great seeing this cutting edge, innovative, forward thinking biotech company progress and derisk along the way.
sure is a great time to be part of it as a shareholder mate...
